If accepted, Vifor Pharma's £23m offer will "claw back" money for the NHS and close the CMA's first-ever disparagement case.

After recently taking steps to undo messaging about a rival product in the European Union, CSL Vifor is carrying its amends ...

The regulator was concerned that this restricted competition by reducing take-up of Monofer, potentially costing the NHS ...

Miners also continued to weigh on the FTSE 100, sending London’s blue-chip index down 46 points to 8,305. The NHS will ...